Literature DB >> 16305617

Emerging viral infections after hematopoietic cell transplantation.

Michael Boeckh1, Veronique Erard, Danielle Zerr, Janet Englund.   

Abstract

This overview summarizes recent data on emerging viruses after hematopoietic cell transplantation (HCT), including adenovirus, BK virus, human metapneumovirus (hMPV), and human herpesvirus (HHV) 6. The increased recognition of these infections is due to improved molecular detection methods, increased surveillance and more profound immunosuppression in the host. Adenovirus can cause serious disease especially in T-cell depleted transplant recipients. Adenovirus viremia is an important risk factor for disease in this setting. BK virus has been associated with hemorrhagic cystitis in HCT recipients. BK viremia is significantly associated with hemorrhagic cystitis. hMPV shows a seasonal distribution and can cause fatal pneumonia in HCT recipients. hMPV may be the etiology of some cases previously categorized as idiopathic pneumonia syndrome. HHV-6 commonly leads to viremia in HCT recipients. HHV-6 has been strongly associated with encephalitis and delayed platelet engraftment. Prospective studies are needed to further examine epidemiology, disease associations, and management strategies for these viruses.

Entities:  

Mesh:

Year:  2005        PMID: 16305617     DOI: 10.1111/j.1399-3046.2005.00442.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  21 in total

Review 1.  NKT cells, Treg, and their interactions in bone marrow transplantation.

Authors:  Holbrook E Kohrt; Asha B Pillai; Robert Lowsky; Samuel Strober
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

2.  Management of Hematuria in Children.

Authors:  O N Ray Bignall; Bradley P Dixon
Journal:  Curr Treat Options Pediatr       Date:  2018-06-14

Review 3.  Human Metapneumovirus: lessons learned over the first decade.

Authors:  Verena Schildgen; Bernadette van den Hoogen; Ron Fouchier; Ralph A Tripp; Rene Alvarez; Catherine Manoha; John Williams; Oliver Schildgen
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

Review 4.  The development of new therapies for human herpesvirus 6.

Authors:  Mark N Prichard; Richard J Whitley
Journal:  Curr Opin Virol       Date:  2014-10-22       Impact factor: 7.090

5.  Benzimidazole analogs inhibit human herpesvirus 6.

Authors:  Mark N Prichard; Samuel L Frederick; Shannon Daily; Katherine Z Borysko; Leroy B Townsend; John C Drach; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

Review 6.  Preventing stem cell transplantation-associated viral infections using T-cell therapy.

Authors:  Ifigeneia Tzannou; Ann M Leen
Journal:  Immunotherapy       Date:  2015-08-07       Impact factor: 4.196

Review 7.  Cytotoxic T lymphocytes as immune-therapy in haematological practice.

Authors:  Ann M Leen; Helen E Heslop
Journal:  Br J Haematol       Date:  2008-08-07       Impact factor: 6.998

8.  Human herpesvirus 6A (HHV-6A) and HHV-6B alter E2F1/Rb pathways and E2F1 localization and cause cell cycle arrest in infected T cells.

Authors:  Guy Mlechkovich; Niza Frenkel
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

9.  Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.

Authors:  Ulrike Gerdemann; Anne S Christin; Juan F Vera; Carlos A Ramos; Yuriko Fujita; Hao Liu; Dagmar Dilloo; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Ann M Leen
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

10.  A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo.

Authors:  John V Williams; Zhifeng Chen; Gabriella Cseke; David W Wright; Christopher J Keefer; Sharon J Tollefson; Ann Hessell; Amy Podsiad; Bryan E Shepherd; Pietro Paolo Sanna; Dennis R Burton; James E Crowe; R Anthony Williamson
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.